Fig. 2: Baseline comparison of PAM50 subtype and differentially expressed genes and pathways between ANA/PAL-sensitive and ANA/PAL-resistant cases. | Nature Communications

Fig. 2: Baseline comparison of PAM50 subtype and differentially expressed genes and pathways between ANA/PAL-sensitive and ANA/PAL-resistant cases.

From: Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

Fig. 2: Baseline comparison of PAM50 subtype and differentially expressed genes and pathways between ANA/PAL-sensitive and ANA/PAL-resistant cases.

A composition of PAM50 subtypes of ANA/PAL-Sensitive or -Resistant tumors. B IHC Ki67 of Sensitive (n = 13 samples) and Resistant tumors (n = 7 samples). Statistics calculated with two-sided Mann–Whitney U test. Boxplot shows the median (center line), the 25th and 75th percentiles (lower and upper box bounds), and whiskers extending to the most extreme data points within 1.5× the interquartile range. C Principal component analysis (PCA) and D volcano plot of differentially expressed genes by DEseq2. −Log10 p-adj values are plotted on the y-axis. E Top oncogenic pathways significantly up or downregulated by Hallmark GSEA analysis in Resistant vs Sensitive tumors.

Back to article page